Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
  • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
  • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
  • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
  • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
  • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
  • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
  • C07C271/06—Esters of carbamic acids
  • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
  • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
  • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
  • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
  • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
  • C07D295/182—Radicals derived from carboxylic acids
  • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Definitions

• the present invention relates to derivatives of 3-(4-fluorophenyl)-3- hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity.
• the present invention also relates to pharmaceutical compositions containing these compounds as active ingredient for alleviating or eliminating pain in mammals and to methods of using said pharmaceutical compositions as analgesics.
• Patent application WO 081273 published on 3 August 2006 also discloses compounds which are structurally related to the compounds shown above.
• A is an amide moiety having a formula CI -7 O I-2 S O -I NI -2 H 2-I6 F O-2 ;
• B is an amine, an N-amide, or sulfonamide moiety having a formula Ci -I2 H 2- 3001-4So-INi-SFo -2 CIo -2 BrO -2 Io ⁇ ; and
• R is H, Ci -6 alkyl, or Ci- 6 acyl.
• These compounds are useful for treating pain.
• a dosage form (such as pill, tablet, or capsule for oral administration, or a liquid for injection) is prepared containing the compound, and the dosage form is administered to a mammal needing the treatment.
• suitable dosage forms are known in the art.
• the dose may vary depending upon the mammal being dosed and the particular condition being treated. A person of ordinary skill in the art can determine the dose appropriate for the situation. For example, for humans, a dose range of 0.5 mg to 1000 mg is contemplated.
• treat refers to the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
• reference to a compound should be construed broadly to include any compounds, pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of a depicted structural formula or chemical name.
• a pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human.
• a pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
• a salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
• a prodrug is a compound which is converted to a therapeutically active compound after administration. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group.
• Prodrug preparation is well known in the art. For example, "Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496-557, provides further detail on the subject.
• Tautomers are isomers that are in rapid equilibrium with one another.
• tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion.
• Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein.
• alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
• Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
• A, B, and R are standard moieties recognized as stable in the art. Unusual structures such as open shell atoms, overstrained rings, and hypervalent atoms are not contemplated. For example, all carbon atoms have 4 covalent bonds in any combination of single, double, or triple bonds, where a double bond counts as 2 covalent bonds, and a triple bond counts as 3 covalent bonds. All hydrogen and halogen atoms have a single covalent bond. All oxygen atoms have 2 covalent bonds. All nitrogen atoms have 3 covalent bonds. Finally, sulfur atoms usually have 2 covalent bonds, but may also form one of the following functional groups:
• A is an amide moiety having a formula Ci. 7 Oi. 2 So-iNi- 2 H2-i6Fo -2 .
• the formula Ci -7 Oi-2So-i NI -2 H 2 -ISF 0-2 means that A has from 1 to 7 carbon atoms, from 1 to 2 oxygen atoms, from 0 to 1 sulfur atoms, from 1 to 2 nitrogen atoms, from 2 to 16 hydrogen atoms, and from 0 to 2 fluorine atoms.
• An amide moiety has the functional group:
• A could be an acyclic amide moiety such as:
• each R 2 is independently hydrogen or linear alkyl, provided that the total number of carbon atoms in A is from 1 to 7.
• R 2 might be Ci -6 alkyl, and the other R 2 might be hydrogen.
• both R 2 could be hydrogen, or both R 2 could be alkyl.
• Ci- 6 alkyl is alkyl having from 1 to 6 carbon atoms, e.g. methyl, ethyl, propyl isomers, butyl isomers, pentyl isomers, hexyl isomers, cyclopropyl, cyclobutyl, cyclopenyl, cyclohexyl, etc.
• Alkyl is a moiety containing only carbon and hydrogen that has only single covalent bonds, i.e. no double or triple bonds are present.
• A could be one of the moieties depicted below.
• A could also be a cyclic amide, meaning that A has a ring as part of the structure.
• the nitrogen attached to the carbonyl of the amide could be part of a cycle.
• this type of amide is referred to as an "N-cyclic amide.”
• Examples of N-cyclic amides include the structures below.
• B is an amine or an N-amide moiety having a formula C1.12H2-30O1-.1S0- iNi.3Fo-2Clo-2Bro-2lo-2
• the formula Ci- ⁇ -soOi ⁇ So-iNi.aFo ⁇ Clo ⁇ Bro ⁇ lo ⁇ means that B has from 1 to 12 carbon atoms, from 2 to 30 hydrogen atoms, from 1 to 4 oxygen atoms, from 0 to 1 sulfur atoms, from 1 to 3 nitrogen atoms, from 0 to 2 fluorine atoms, from 0 to 2 chlorine atoms, from 0 to 2 bromine atoms, and from 0 to 2 iodine atoms.
• An amine moiety has the functional group:
• B might be a linear alkyl amine, meaning a moiety having the formula -NH-Ci -6 alkyl, wherein the alkyl is linear.
• B might also be a benzylic amine, meaning a moiety having the formula
• B might also be an N-amide.
• An N-amide moiety has the functional group: where one of the 2 bonds from the N attaches to the remainder of the molecule, and 1 of the bonds from the N and the bond from the carbonyl carbon to the remainder of the N-amide moiety (i.e. the remaining part of B).
• Ph is substituted or unsubstituted phenyl. Any substituent may be present on phenyl, provided that it conforms to the constrains for B defined herein. Examples of useful substituents include F, Cl, Br, I, OH, NH 2 , Ci -6 alkyl, 0-(Ci -6 alkyl), S-(Ci -6 alkyl), CO 2 H, and CN.
• the Ci -6 alkyl depicted above is linear.
• a sulfonamide moiety has a formula :
• each R 3 are independently any moiety that conforms to the constraints for B defined herein.
• H and Ci -6 alkyl are particularly contemplated for R 3 . Examples include:
• R is H, Ci-6 alkyl or C- ⁇ -6 acyl.
• Acyl is
• H, -COCH 3 and methyl are examples of useful moieties for R.
• R is H.
• A is :
• B is NH 2 .
• the compound above is the erythro form.
• the compound above is the (+)-enantiomer of the erythro form.
• the compound above is the (-)-enantiomer of the erythro form.
• the compound above is the threo form.
• the compound above is the (+)-enantiomer of the threo form.
• the compound above is the (-)-enantiomer of the threo form.
• Another embodiment is a method of treating pain comprising administering a compound according to the invention to a mammal in need thereof.
• Another embodiment is use of a compound according to the invention in the manufacture of a medicament for the treatment of pain in a mammal.
• Another embodiment is a dosage form comprising a compound according to the invention and a pharmaceutically acceptable excipient.
• SLA 19084 The secondary alcohol function of SLA 19084 was oxidized at room temperature using the Dess-Martin periodinane in dichloromethane to afford to the dioxo derivative, SLA 19086, in 76% yield.
• Enantiomers (+)-erythro Compound 5 and (-)-erythro Compound 6 were obtained in 34.5% yield each from the free base of racemic Compound 4 (prepared from Compound 4 HCI salt using Amberlite OH " resin in MeOH) by a semi-preparative chiral HPLC separation using a Sepapak ® -2 HR column (250x4.6 mm, 3 ⁇ m) followed by a 0.25 N aqueous HCI treatment in EtOH. Enantiomeric excesses (e.e.) of 98.6% for Compound 5 and 98.2% for Compound 6, were measured by analytical chiral HPLC using a Sepapak ® -2 HR column.
• Amides SLA 19136, SLA 07116B or SLA 19098 were separately reacted with 4-fluorobenzaldehyde in presence of KOH in MeOH at 0 0 C to produce diastereoselectively (diastereoisomeric excess d.e.>96%) the ( ⁇ ytrans oxazolines, SLA 19142, SLA 19138 or SLA 19180, respectively, in 24-91 % yields.
• Final ring opening of the oxazolines SLA 19142, SLA 19138 or SLA 19180 by an aqueous HCI solution in MeOH at 50 0 C afforded Compounds 7, 8, and 9, respectively, in 53-85% yield.
• LPO 22182 was coupled with 4- methoxypiperidine using the EDCI - HOBT method in dichloromethane at 4°C to RT for 15 h to give the £-Boc protected amide, LPO 26092, in 60% yield.
• Amide LPO 26092 was deprotected by treatment with trifluoroacetic acid in dichloromethane for 15 min at RT to afford Compound 11 , which was subsequently treated for 15 min at 4°C with a 1.56 N HCI solution in MeOH to obtain Compound 11 in 52% yield.
• amides A, B and TTA 24064 were deprotected by treatment by trifluoroacetic acid in dichloromethane for one hour (15 h for TTA 24064) at RT to afford to Compounds 12, 13 and 18, respectively, as the free bases.
• Separate methanolic solutions of Compound 12 and 13 were treated for 10 min at RT with 2N HCI solutions in diethyl ether (a 0.2N HCI solution in MeOH was used for Compound 18 free base) to obtain Compounds 12, 13 and 18, respectively, in 33% to 66% yields.
• Compound 17 was obtained in three synthetic steps from Compound 3.
• Compound 3 in dichloromethane was treated overnight at RT with di-ferf-butyl dicarbonate in the presence of triethylamine and a catalytic quantity of DMAP to afford the f-Boc protected derivative CCH 23140-1 in 95% yield.
• CCH 23140-1 was reacted overnight at RT with acetic acid in the presence of diisopropylaminomethyl resin and a catalytic quantity of DMAP to give the t- Boc protected acetate, CCH 23140-2, in 70% yield.
• CCH 23140-2 was treated for 1 h at RT with a solution of HCI in diethyl ether to obtain Compound 17 in 98% yield.
• Examples of useful compounds include:
• HPLC Method A Compounds were analyzed by reverse phase high performance liquid chromatography (HPLC) using a Waters Autopurification
• HPLC Method B Compounds were analyzed by reverse phase high performance liquid chromatography (HPLC) using a Waters System equipped with a Waters 600 Pump, a Waters 996 photodiode array detector, and a XTerra column (Part. No. 191372972, 5 ⁇ m, RP18, 4.6 * 250 mm).
• HPLC Chiral Analysis were performed on an unit composed of Merck D-7000 system manager, Merck-Lachrom L-7100 pump, Merck- Lachrom L-7200 autosampler, Merck-Lachrom L-7360 oven, Merck-Lachrom L-7400 UV-detector and a Jasco OR-1590 polarimeter.
• analytical chiral separation was performed on a Chiralpak ® IA column (Daicel, 250x4.6 mm, 5 ⁇ m) available from Chiral Technology Europa (lllkirch, France).
• the optical rotatory powers of the salts were measured on a 241 MC Perkin-Elmer polarimeter with a sodium lamp (589 nm), a mercury lamp (578, 546 and 436 nm) and a double-jacketed 10 cm cell at 25°C.
• Compound 3 has been identified as (2R,3S)-2-amino-3-(4- fluorophenyl)-3-hydroxy-1 -(pyrrolidin-1 -yl)propan-1 -one hydrochloride sesquihydrate by single crystal X-Ray diffraction ( Figures 7 & 8).
• Compound 2 has been assigned as (2S,3R)-2-amino-3-(4- fluorophenyl)-3-hydroxy-1 -(pyrrolidin-1 -yl)propan-1 -one hydrochloride.
• 100 mg of the crude product was purified by preparative HPLC using as eluent a gradient from 0% eluent B to 12% eluent B in eluent A in 7 min. with a Prep C18 Xterra ® 19x50 mm column 186001108 - Eluent A: H 2 O (0.05% TFA), eluent B: CH 3 CN (0.05% TFA).
• LPO 2610OB a white oil (140 mg).
• This solid (522 mg, 1.81 mmol) was dissolved in MeOH (6 ml_) and a 2 N HCI solution in Et 2 O (1.80 ml_, 3.60 mmol) was slowly added. The reaction mixture was stirred at RT for 10 min.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pain & Pain Management (AREA)
• Public Health (AREA)
• Rheumatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyrrole Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Hydrogenated Pyridines (AREA)

Priority Applications (7)

Applications Claiming Priority (4)

Publications (1)

Family

ID=40568212

Family Applications (1)

Country Status (11)

Cited By (3)

Families Citing this family (1)

Citations (2)

Family Cites Families (5)

• 2009
  • 2009-02-03 US US12/364,930 patent/US8168631B2/en active Active
  • 2009-02-04 BR BRPI0907482A patent/BRPI0907482A2/pt not_active IP Right Cessation
  • 2009-02-04 CA CA2714398A patent/CA2714398A1/en not_active Abandoned
  • 2009-02-04 KR KR1020107019698A patent/KR20100126345A/ko not_active Withdrawn
  • 2009-02-04 AU AU2009212519A patent/AU2009212519A1/en not_active Abandoned
  • 2009-02-04 MX MX2010008586A patent/MX2010008586A/es active IP Right Grant
  • 2009-02-04 EP EP09708345.5A patent/EP2252583B1/en not_active Not-in-force
  • 2009-02-04 JP JP2010545959A patent/JP2011512334A/ja active Pending
  • 2009-02-04 CN CN2009801118205A patent/CN101998950A/zh active Pending
  • 2009-02-04 WO PCT/US2009/033014 patent/WO2009100095A1/en not_active Ceased
  • 2009-02-04 RU RU2010135794/04A patent/RU2010135794A/ru not_active Application Discontinuation

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events